Antitumor effect of Gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, combined with cytotoxic agent on murine hepatocellular carcinoma

Table 3 Effect of Gefitinib or/and CDDP on BW, TI, and SI of mice bearing H22 tumors (mean±SD).

Groups	n		SI		TI		BW prior to treatment (g)		BW at sacrifice (g)		Net BW at sacrifice (g)
	Exp 1	Exp 2	Exp 1	Exp 2	Exp 1	Exp 2	Exp 1	Exp 2	Exp 1	Exp 2	Exp 1	Exp 2
Lecithin control	14	14	92.1±34.9	76.9±18.0	53.9±13.2	45.2±7.9	16.5±1.0	19.5±1.0	26.6±4.2	28.3±2.0	25.1±4.4	27.5±2.0
NS control	13	14	92.7±35.0	75.7±17.2	52.6±14.2	46.3±8.0	16.5±0.9	19.4±0.8	25.6±4.0	28.3±2.0	25.0±3.8	27.5±2.0
CDDP d1-5	14	13	70.2±17.9b	56.0±16.0b	40.3±5.8a	35.9±4.1a	16.6±0.8	19.8±0.9	22.9±1.5	26.9±2.7	22.3±1.3	25.9±2.7
CDDP d6-10	12	14	59.0±11.9b	52.8±12.9b	39.7±4.9a	35.1±6.3a	16.6±0.8	18.9±0.7	22.0±2.1a	25.3±3.0b	21.2±2.1a	24.4±2.9b
Gefitinib d1-10	14		91.3±21.5		46.3±7.7		16.5±0.9		24.6±2.8		23.8±2.9
Gefitinib d1-5		14		83.6±22.5		41.4±8.0		19.7±0.8		28.0±1.4		27.4±1.5
Gefitinib d1-10	13		59.3±32.5b		39.6±5.1a		16.4±1.0		17.6±2.1b		16.9±2.1b
+CDDP d1-5
Gefitinib d1-10	14		51.7±14.5b		39.7±8.4a		16.5±0.9		19.9±1.6b		18.8±1.6b
+CDDP d6-10
Gefitinib d1-5		14		56.4±8.4b		35.8±4.1a		18.9±0.8		24.6±1.4b		23.7±1.4b
+CDDP d1-5
CDDPd1-5		13		54.5±16.4b		34.6±5.8a		19.7±0.7		24.1±2.3b		24.1±2.3b
→Gefitinib d6-10
Gefitinib d1-5		13		46.3±12.6b		34.1±6.1a		18.9±0.7		24.8±2.4b		24.3±2.3b
→CDDP d6-10

^aP<0.05,

^bP<0.01 vs gefitinib (d1-5 or d1-10) group, BW: body weight, SI: spleen index [10 × weight of spleen (mg)/BW(g)], TI: thymus index [10 × weight of thymus (mg)/BW (g)], Exp 1: first experiment, Exp 2: second experiment.